Please note that we have relocated to a new location. We now accept selected PPO insurances. For the protection of our patients, the staff will wear mask in the office. For Telehealth follow-up and new consultations please contact us here.
1-818-812-7222
1-818-812-7222 Office Hours: Monday Thru Friday: By Appointment only

5170 Sepulveda Blvd. Suite 210
Sherman Oaks, California 91403

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Link to Scientific Article :
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Date of Publication: April 2020

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) causes significant mortality. It is therefore important to minimize the inflammatory response.